Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmel J Pezaro

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|January 11, 2012
MDV3100 for the treatment of prostate cancerDeborah Mukherji, Carmel J Pezaro, Johann S De-Bono
Drug Discovery Today|December 27, 2011
Abiraterone acetate: redefining hormone treatment for advanced prostate cancerCarmel J Pezaro, Deborah Mukherji, Johann S De Bono
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
The Winds of Change: Emerging Therapeutics in Prostate CancerCarmel J Pezaro, Ariel E Marciscano, Ravi A Madan
Expert Review of Anticancer Therapy|October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancerTimothy A Yap, Carmel J Pezaro, Johann S de Bono
Cancer Treatment Reviews|January 8, 2013
New treatment developments applied to elderly patients with advanced prostate cancerDeborah Mukherji, Carmel J Pezaro, Ali Shamseddine, et al.
BJU International|May 16, 2019
Circulating oestrogen receptor mutations and splice variants in advanced prostate cancerLiang G Qu, Hady Wardan, Ian D Davis, et al.
European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
Molecular Cancer Therapeutics|August 20, 2021
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP InhibitionMitchell G Lawrence, Laura H Porter, Nicholas Choo, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Nature Communications|August 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncologyGail P Risbridger, Ashlee K Clark, Laura H Porter, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|January 11, 2012
MDV3100 for the treatment of prostate cancerDeborah Mukherji, Carmel J Pezaro, Johann S De-Bono
Drug Discovery Today|December 27, 2011
Abiraterone acetate: redefining hormone treatment for advanced prostate cancerCarmel J Pezaro, Deborah Mukherji, Johann S De Bono
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
The Winds of Change: Emerging Therapeutics in Prostate CancerCarmel J Pezaro, Ariel E Marciscano, Ravi A Madan
Expert Review of Anticancer Therapy|October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancerTimothy A Yap, Carmel J Pezaro, Johann S de Bono
Cancer Treatment Reviews|January 8, 2013
New treatment developments applied to elderly patients with advanced prostate cancerDeborah Mukherji, Carmel J Pezaro, Ali Shamseddine, et al.
BJU International|May 16, 2019
Circulating oestrogen receptor mutations and splice variants in advanced prostate cancerLiang G Qu, Hady Wardan, Ian D Davis, et al.
European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.
Molecular Cancer Therapeutics|August 20, 2021
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP InhibitionMitchell G Lawrence, Laura H Porter, Nicholas Choo, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Nature Communications|August 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncologyGail P Risbridger, Ashlee K Clark, Laura H Porter, et al.
Pageof 2